medigraphic.com
ISSN 0210-5187 (Electronic)

2014, Number 1-3

<< Back Next >>

Med Cutan Iber Lat Am 2014; 42 (1-3)

Moderate and severe cellulitis admitted to hospital. Hospitalization criteria and empirical antibiotic therapy

Perelló-Alzamora MR, Santos-Durán JC, Fernández-López E

Language: Spanish
References: 22
Page: 12-17
PDF size: 253.83 Kb.


ABSTRACT

Cellulitis is an inflammatory skin condition with an infectious origin which affects the deep dermis and the subcutaneous tissue. It is generally not considered severe infection. However, being most common in the elderly and patients with basal comorbidities, sometimes they may require admission. To date, there is no accepted consensus regarding the admission criteria and empirical antibiotic therapy. Accordingly, before revising the issue, we propose a standardized protocol which includes admission criteria and empirical antibiotic therapy.


REFERENCES

  1. Swartz MN. Clinical practice. Cellulitis. N Engl J Med. 2004; 350: 904-912.

  2. Figtree M, Konecny P, Jennings Z, Goh C, Krilis SA, Miyakis S. Risk stratification and outcome of cellulitis admitted to hospital. J Infect. 2010; 60: 431-439.

  3. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005; 41: 1373-406.

  4. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005; 49: 2260-2266.

  5. Carratala J, Roson B, Fernández-Sabe N, Shaw E, del Rio O, Rivera A et al. Factors associated with complications and mortality in adult patients hospitalized for infectious cellulitis. Eur J Clin Microbiol Infect Dis. 2003; 22: 151-157.

  6. Lazzarini L, Conti E, Tositti G, de Lalla F. Erysipelas and cellulitis: clinical and microbiological spectrum in an Italian tertiary care hospital. J Infect. 2005; 51: 383-389.

  7. Concheiro J, Loureiro M, González-Vilas D, García-Gavín J, Sánchez-Aguilar D, Toribio J. Erisipelas y celulitis. Estudio retrospectivo de 122 casos. Actas Dermosifiliogr. 2009; 100: 888-94.

  8. Dupuy A, Benchikhi H, Roujeau JC, Bernard P, Vaillant L, Chosidow O et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ. 1999; 318 (7198): 1591-1594.

  9. Chartier C, Grosshans E. Erysipelas: an update. Int J Dermatol. 1996; 35: 779-81.

  10. Roujeau JC, Sigurgeirsson B, Korting HC, Kerl H, Paul C. Chronic Dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study. Dermatology. 2004; 209: 301-307.

  11. Martín JM, Molina I, Ramón D, Monteagudo C, Alonso V, Jordá E. Infección subcutánea necrotizante por Streptococcus agalactiae. Actas Dermosifiliogr. 2006; 97: 644-646.

  12. Rodríguez-Vázquez M, García-Arpa M, Porras-Leal L, Romero-Aguilera G, Cortina de la Calle P, Romero-Aguilera MD. Celulitis atípica asociada a bacteriemia por Campylobacter jejuni en un paciente con hipogammaglobulinemia ligada al cromosoma X. Actas Dermosifiliogr. 2004; 95: 41-43.

  13. Lebre C, Girard-Pipau F, Roujeau JC, Revuz J, Saiag P, Chosidow O. Value of fine-needle aspiration in infectious cellulitis. Arch Dermatol. 1996; 132: 842-843.

  14. Stevens D. Treatments for skin and soft-tissue and surgical site infections due to MDR Gram-positive bacteria. J Infect. 2009; 59 (Suppl 1): S32-39.

  15. Mensa J GJ, García-Sánchez J, Letang E. Guía de Terapéutica Antimicrobiana 2010. Barcelona. Ed. Escofet Zamora, 2010.

  16. Hepburn MJ, Dooley DP, Skidmore PJ, Ellis MW, Starnes WF, Hasewinkle WC. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med. 2004; 164: 1669-1674.

  17. Bergkvist PI, Sjobeck K. Relapse of erysipelas following treatment with prednisolone or placebo in addition to antibiotics: a 1-year follow-up. Scand J Infect Dis. 1998; 30: 206-207.

  18. Jorup-Ronstrom C, Britton S. Recurrent erysipelas: predisposing factors and costs of prophylaxis. Infection. 1987; 15: 105-6.

  19. Morris A. Cellulitis and erysipelas. Clin Evid. 2006; (15): 2207-2211.

  20. Kremer M, Zuckerman R, Avraham Z, Raz R. Long-term antimicrobial therapy in the prevention of recurrent soft-tissue infections. J Infect. 1991; 22: 37-40.

  21. Kasseroller R. Sodium selenite as prophylaxis against erysipelas in secondary lymphedema. Anticancer Res. 1998; 18 (3C): 2227-2230.

  22. Tan R, Newberry DJ, Arts GJ, Onwuamaegbu ME. The design, characteristics and predictors of mortality in the North of England Cellulitis Treatment Assessment (NECTA). Int J Clin Pract. 2007; 61: 1889-1893.




2020     |     www.medigraphic.com